Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celsion Corporation
Celsion Announces Promising ThermoDox® Clinical Results in Primary Liver Cancer Were Published in Expert Opinion
April 14th, 2009
Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced that promising Phase 1 ThermoDox clinical results in hepatocellular carcinoma (HCC) or primary liver cancer have been published in the peer-reviewed medical journal Expert Opinion on Pharmacology. The review article titled "Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer" was published in the February issue (Expert Opin. pharmacother. (2009)10(2):333-343). ThermoDox is a proprietary formulation of lyso-thermosensitive liposomal doxorubicin (LTLD) used in combination with radiofrequency ablation (RFA) to provide...
Source: Cancer Weekly (2009-04-14)
|
